NAMS Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Newamsterdam Pharma Company (NAMS) following the 2026 Q2 hedge fund 13F filings?

As of today, NAMS has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), NAMS gained -20.4% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Newamsterdam Pharma Company (NAMS)

166 + Investors. Track Smart Money conviction in NAMS. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — NAMS

Based on 169 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their NAMS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

📊

High ownership — 92% of 3.0Y peak

92% of all-time peak

169 funds currently hold this stock — 92% of the 3.0-year high of 183 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.

🚀

Fast accumulation — +33% more funds vs a year ago

fund count last 6Q

+42 new funds entered over the past year (+33% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 52% buying

97 buying89 selling

Last quarter: 97 funds bought or added vs 89 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-32 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 25 → 22 → 58 → 26. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 32% entered in last year

■ 22% conviction (2yr+) ■ 46% medium ■ 32% new

Only 38 funds (22%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

🚀

Acceleration phase — new buyers rushing in

26 → 25 → 22 → 58 → 26 new funds/Q

New funds entering each quarter: 25 → 22 → 58 → 26. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

📊

Mixed cohorts — 19% veterans, 43% new entrants

■ 19% veterans ■ 38% 1-2yr ■ 43% new

Of 178 current holders: 33 (19%) held 2+ years, 68 held 1–2 years, 77 (43%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

✅

Strong quality — 36% AUM from major funds

36% from top-100 AUM funds

46 of 167 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.1

out of 10

Moderate Exit Risk

Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	166	182	-8.79%
13F Shares	123M	119M	3.0%
Total Value	$3.80B	$4.18B	-9.12%
New Positions	24	57	-33
Increased Positions	68	54	+14
Closed Positions	40	13	+27
Reduced Positions	46	50	-4
Total Calls	5	5	-
Total Puts	6	4	50.0%
PUT/CALL Ratio	1.2	0.8	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

166

182

-8.79%

13F Shares

123M

119M

3.0%

Total Value

$3.80B

$4.18B

-9.12%

New Positions

-33

Increased Positions

+14

Closed Positions

+27

Reduced Positions

-4

Total Calls

Total Puts

50.0%

PUT/CALL Ratio

1.2

0.8

Neutral

Institutional Holders (2026 Q2)

166 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NAMS. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 NAMS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Medicxi Ventures Management (Jersey) Ltd	42.19%	2,208,639	$74.9M
2	Fcpm III Services B.V.	38.34%	8,490,353	$287.7M
3	Frazier Life Sciences Management, L.P.	13.35%	18,088,902	$613.0M
4	Bain Capital Life Sciences Investors, LLC	7.67%	3,806,566	$129.0M
5	Artia Global Partners LP	3.15%	503,936	$17.1M
6	Ra Capital Management, L.P.	2.81%	9,550,191	$323.7M
7	Atle Fund Management AB	2.27%	248,848	$8.4M
8	First Turn Management, LLC	2.11%	582,497	$19.7M
9	Deerfield Management Company, L.P.	1.51%	4,264,789	$144.5M
10	Maverick Capital Ltd	0.98%	3,267,802	$110.7M
11	Rock Springs Capital Management LP	0.96%	582,744	$19.7M
12	Ishara Investments LP	0.92%	36,900	$1.3M
13	Cormorant Asset Management, LP	0.87%	500,000	$16.9M
14	DCF Advisers, LLC	0.84%	141,000	$4.8M
15	Decheng Capital LLC	0.82%	176,887	$6.0M
16	Moody Aldrich Partners LLC	0.55%	90,617	$3.1M
17	Eversept Partners, LP	0.48%	275,471	$9.3M
18	Stempoint Capital LP	0.45%	77,589	$2.6M
19	AlphaCentric Advisors LLC	0.43%	14,868	$504K
20	Affinity Asset Advisors, LLC	0.42%	275,000	$9.3M
21	Viking Global Investors LP	0.41%	4,203,567	$142.5M
22	Fieldview Capital Management, LLC	0.40%	41,842	$1.4M
23	Fox Run Management, L.L.C.	0.33%	59,477	$2.0M
24	ArrowMark Colorado Holdings LLC	0.30%	211,843	$7.2M
25	Headlands Technologies LLC	0.26%	72,335	$2.5M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Newamsterdam Pharma Company (NAMS)

What does the Smart Money Trend signal show for NAMS?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their NAMS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for NAMS?

Slight buying edge — 52% buying: Last quarter: 97 funds bought or added vs 89 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for NAMS holders?

Strong quality — 36% AUM from major funds: 46 of 167 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held NAMS?

Mostly new holders — 32% entered in last year: Only 38 funds (22%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Newamsterdam Pharma Company (NAMS) following the 2026 Q2 hedge fund 13F filings?

As of today, NAMS has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), NAMS has gained -20.4% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Newamsterdam Pharma Company (NAMS)

Smart Money Signals — NAMS

Selling streak — 1 quarter in a row

High ownership — 92% of 3.0Y peak

Fast accumulation — +33% more funds vs a year ago

Slight buying edge — 52% buying

Fewer new buyers each quarter (-32 vs last Q)

Mostly new holders — 32% entered in last year

Acceleration phase — new buyers rushing in

Mixed cohorts — 19% veterans, 43% new entrants

Strong quality — 36% AUM from major funds

Institutional Sentiment Summary — NAMS

Hedge Fund Ownership: NAMS

Market Analysis: NAMS

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: NAMS

Is It Too Late to Buy Newamsterdam Pharma Company (NAMS) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: NAMS

Statistics: NAMS

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Newamsterdam Pharma Company (NAMS)

Welcome to 13Foresight!